Compare Gogoro Inc (GGR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Gogoro Inc trades at $3.86 (market cap $77.38M), while State Street SPDR S&P Biotech ETF trades at $153.57. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.
| GGR | XBI | |
|---|---|---|
Market Cap | $77.38M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $7.89 | $164.28 |
52-Week Low | $2.74 | $85.16 |
Enterprise Value | $379.83M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
